An Emerging Markets News Commentary
ORLANDO, Oct. 02, 2019 (GLOBE NEWSWIRE) -- When Botox hit the annals of pop culture as a beauty product, a healer, and more it was shocking to many. How could a product derived from the notorious toxin Clostridium botulinum, the stuff that causes botulism, serve the greater good? Until these very recent medical breakthroughs botulism was mostly associated with deathly paralysis.
But as the toxin was harnessed to fix headaches, wrinkles, excessive sweating… even urinary incontinence… Botox has a far more appealing reputation than its lethal origins. It’s a good guy.
Today it appears that deadly Anthrax may be breaking good as Botox has, intent on joining the ranks of the helpful and the healers while eschewing its well-earned infamy for contributing to the actual Fall of Rome and more recently, a domestic bio-terrorism event that had the nation on edge. Indeed, U.S. based Spherix Inc. (SPEX) believes that Anthrax could very well be used to effectively fight ovarian cancer.
Spherix, which partners with leading U.S. based universities to develop and eventually monetize groundbreaking drug discoveries, has executed an exclusive option agreement with the University of Maryland, Baltimore (UMB) related to its anticancer drug designated PrAg-PAS. This novel protein drug is designed by re-engineering the Anthrax toxin delivery mechanism so that any one of a number of anticancer drug payloads may be specifically transported into ovarian cancer cells.
Spherix’s CEO Anthony Hayes describes the discovery: “In simple terms, they have modified the Anthrax toxin so that it kills cancer cells, but not other cells. By using an elegant protein engineering strategy, the inventors have hijacked the complex anthrax toxin delivery mechanism to create a highly efficient drug delivery system specific to ovarian cancer cells. In mouse models tested, the data show that tumor growth halted following treatment with PrAg-PAS and did not increase compared to the control mice.”
It is a staggering prospect to consider, this Anthrax-as-a-Good-Guy possibility. And of course the drug is still in relatively early stages of development, the successful mouse tests notwithstanding.
But it is also the type of intriguing, compelling story that will be followed by many who wish to see if the notorious Anthrax can be harnessed to fight a far worse villain in ovarian cancer. If it does, Spherix certainly holds an exclusive option agreement that it has added to its growing portfolio in the Life Sciences.
The Emerging Markets Report is owned and operated by Emerging Markets Consulting (EMC), a syndicate of investor relations consultants representing years of experience. Our network consists of stockbrokers, investment bankers, fund managers, journalists and institutions that actively seek opportunities in the micro and small-cap equity markets.
For more informative reports such as this, please sign up at http://www.emergingmarketsllc.com/newsletter.php
Section 17(b) of the Securities Act of 1933 requires that any person that uses the mails to publish, give publicity to, or circulate any publication or communication that describes a security in return for consideration received or to be received directly or indirectly from an issuer, underwriter, or dealer, must fully disclose the type of consideration (i.e. cash, free trading stock, restricted stock, stock options, stock warrants) and the specific amount of the consideration. In connection therewith, EMC has received the following compensation and/or has an agreement to receive in the future certain compensation, as described below.
We may purchase Securities of the Profiled Company prior to their securities becoming publicly traded, which we may later sell publicly before, during or after our dissemination of the Information, and make profits therefrom. EMC does not verify or endorse any medical claims for any of its client companies.
EMC has been paid 125,000 dollars by Spherix for various marketing services including this report. EMC does not independently verify any of the content linked-to from this editorial. http://emergingmarketsllc.com/disclaimer.php
A contributor to this report receives $3,500 per month as a consultant to Spherix
This Commentary may include forward-looking statements and involve risks and uncertainties which could cause actual results to differ materially from those in the forward-looking statements contained herein with respect to the Profiled Company. No information in this Commentary should be construed as any indication whatsoever of the Profiled Company's future financial results, revenues or stock price.